Pozen Inc. (POZN)

[Tina]

There's no link nor date because that's a 2008 reco and not recent.

I have no idea why people think posting on a message board positive or negative is going to have any influence on how a stock like POZN is going to trade.

Guess pink sheet mentality of posters here.

April 16, 2008 9:39 AM EDT

Citi maintains 'Buy' rating on POZEN (Nasdaq: POZN). Price target increased from $15 to $19.

Citi analyst says, "Treximet has received FDA approval. We expect Treximet to gain significant market share in the $2 billion migraine market, as Glaxo (Nasdaq: GSK) intends to aggressively convert its Imitrex sales (55% of the migraine market) to Treximet. We believe POZEN has a solid product pipeline that targets a significant market opportunity. PN 400, which is a combination of AstraZeneca's Nexium (NYSE: AZN) and naproxen, would target the $3B market left vacant by Cox-2 inhibitor drug class (e.g. Vioxx and Bextra). POZN recently announced positive proof of concept results for PA 325, an aspirin-PPI combination that helps reduce the risk of cardiovascular disease while reducing or eliminating the side effects that are normally associated with chronic aspirin use. We believe a partnership announcement for PA325 would be a positive catalyst for the stock."